176 related articles for article (PubMed ID: 31358544)
1. Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study.
Paoletti C; Miao J; Dolce EM; Darga EP; Repollet MI; Doyle GV; Gralow JR; Hortobagyi GN; Smerage JB; Barlow WE; Hayes DF
Clin Cancer Res; 2019 Oct; 25(20):6089-6097. PubMed ID: 31358544
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
4. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
6. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
7. Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
Paoletti C; Schiavon G; Dolce EM; Darga EP; Carr TH; Geradts J; Hoch M; Klinowska T; Lindemann J; Marshall G; Morgan S; Patel P; Rowlands V; Sathiyayogan N; Aung K; Hamilton E; Patel M; Armstrong A; Jhaveri K; Im SA; Iqbal N; Butt F; Dive C; Harrington EA; Barrett JC; Baird R; Hayes DF
Clin Cancer Res; 2018 Dec; 24(23):5860-5872. PubMed ID: 30082476
[TBL] [Abstract][Full Text] [Related]
8. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
[TBL] [Abstract][Full Text] [Related]
9. Detection of circulating tumor cells in breast cancer patients: prognostic predictive role.
Turker I; Uyeturk U; Sonmez OU; Oksuzoglu B; Helvaci K; Arslan UY; Budakoglu B; Alkis N; Aksoy S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(3):1601-7. PubMed ID: 23679243
[TBL] [Abstract][Full Text] [Related]
10. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.
Smerage JB; Budd GT; Doyle GV; Brown M; Paoletti C; Muniz M; Miller MC; Repollet MI; Chianese DA; Connelly MC; Terstappen LW; Hayes DF
Mol Oncol; 2013 Jun; 7(3):680-92. PubMed ID: 23538216
[TBL] [Abstract][Full Text] [Related]
11. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
Paoletti C; Li Y; Muñiz MC; Kidwell KM; Aung K; Thomas DG; Brown ME; Abramson VG; Irvin WJ; Lin NU; Liu MC; Nanda R; Nangia JR; Storniolo AM; Traina TA; Vaklavas C; Van Poznak CH; Wolff AC; Forero-Torres A; Hayes DF;
Clin Cancer Res; 2015 Jun; 21(12):2771-9. PubMed ID: 25779948
[TBL] [Abstract][Full Text] [Related]
12. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cell count and thrombosis in metastatic breast cancer.
Beinse G; Berger F; Cottu P; Dujaric ME; Kriegel I; Guilhaume MN; Diéras V; Cabel L; Pierga JY; Bidard FC
J Thromb Haemost; 2017 Oct; 15(10):1981-1988. PubMed ID: 28779538
[TBL] [Abstract][Full Text] [Related]
14. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.
Liu XR; Shao B; Peng JX; Li HP; Yang YL; Kong WY; Song GH; Jiang HF; Liang X; Yan Y
Breast; 2017 Apr; 32():119-125. PubMed ID: 28157583
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
Bidard FC; Fehm T; Ignatiadis M; Smerage JB; Alix-Panabières C; Janni W; Messina C; Paoletti C; Müller V; Hayes DF; Piccart M; Pierga JY
Cancer Metastasis Rev; 2013 Jun; 32(1-2):179-88. PubMed ID: 23129208
[TBL] [Abstract][Full Text] [Related]
17. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.
Smerage JB; Barlow WE; Hortobagyi GN; Winer EP; Leyland-Jones B; Srkalovic G; Tejwani S; Schott AF; O'Rourke MA; Lew DL; Doyle GV; Gralow JR; Livingston RB; Hayes DF
J Clin Oncol; 2014 Nov; 32(31):3483-9. PubMed ID: 24888818
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.
Helissey C; Berger F; Cottu P; Diéras V; Mignot L; Servois V; Bouleuc C; Asselain B; Pelissier S; Vaucher I; Pierga JY; Bidard FC
Cancer Lett; 2015 May; 360(2):213-8. PubMed ID: 25700777
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.
Liu MC; Shields PG; Warren RD; Cohen P; Wilkinson M; Ottaviano YL; Rao SB; Eng-Wong J; Seillier-Moiseiwitsch F; Noone AM; Isaacs C
J Clin Oncol; 2009 Nov; 27(31):5153-9. PubMed ID: 19752342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
